Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are pleased to present the latest issue of touchREVIEWS in Endocrinology, which offers a timely and thoughtprovoking collection of articles that reflect both the continuity and evolution of diabetes and metabolic disease research. In an era where technology, public health priorities and clinical paradigms are shifting rapidly, this issue highlights the importance of evidence-based […]

Gian Paolo Fadini, EASD 2021: Real-world Data from the RESTORE-2 Study

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 15th 2021

touchENDOCRINOLOGY caught up with Prof Gian Paolo Fadini (University Hospital of Padova, Italy) virtually during the EASD Annual Meeting 2021 conference to discuss the real-world data from the RESTORE-2 study.

Questions
1. What have randomized controlled trials taught us about the efficacy and safety of second-generation basal insulins? (00:18-01:31)
2. What were the aims, design and inclusion criteria of your study? (01:31-02:44)
3. What were the baseline characteristics of the study cohort? (02:44-03:34)
4. What were the primary and secondary outcome measures and how well were they achieved? (03:34-04:45)
5. What were the conclusions of the investigators and what questions remain unanswered? (04:45-05:57)

Speaker Disclosure: Gian Paolo Fadini is a consultant for Novo Nordisk, Sanofi, Lilly and Abbott. He has received lecture fees from Abbott, Astra Zeneca, Boehinger, Lilly, MSD, Novo Nordisk, Takeda and Sanofi.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Louise Taylor.

Filmed in coverage of the EASD Annual Meeting 2021

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup